Analyst Reco. Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Market Closed - Nasdaq Other stock markets 21:00:00 29/04/2024 BST			5-day change	1st Jan Change
892.5 ^USD	+1.05%		-1.64%	+1.62%

04-26	Regeneron Faces Q1 Seasonality Despite Eylea HD Launch, Oppenheimer Says	MT
04-26	Oppenheimer Adjusts Price Target on Regeneron Pharmaceuticals to $1,175 From $1,125	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Oppenheimer Adjusts Price Target on Regeneron Pharmaceuticals to $1,175 From $1,125	04-26	MT
TD Cowen Adjusts Regeneron Pharmaceuticals' Price Target to $1,030 From $1,020, Keeps Buy Rating	04-24	MT
UBS Adjusts Regeneron Pharmaceuticals Price Target to $1,099 From $1,090, Maintains Buy Rating	04-17	MT
ANALYST RECOMMENDATIONS : Las Vegas Sands, Regeneron, Kinder Morgan, Rivian, Royal Caribbean...	04-17
Goldman Sachs Adjusts Regeneron Pharmaceuticals Price Target to $1,126 From $1,121, Buy Rating Kept	04-15	MT
Morgan Stanley Raises Price Target on Regeneron Pharmaceuticals to $1,177 From $1,115, Keeps Overweight Rating	04-09	MT
Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals	03-25	MT
Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals	03-22	MT
Intellia Therapeutics Ends Co-Development Agreement With Regeneron	03-22	DJ
Morgan Stanley Raises Price Target on Regeneron Pharmaceuticals to $1,115 From $1,104, Maintains Overweight Rating	03-13	MT
RBC Raises Price Target on Regeneron Pharmaceuticals to $1,184 From $1,096, Keeps Outperform Rating	02-27	MT
RBC Trims Price Target on Regeneron Pharmaceuticals to $1,096 From $1,110, Keeps Outperform Rating	02-22	MT
Cantor Fitzgerald Adjusts Price Target on Regeneron Pharmaceuticals to $925 From $850, Keeps Neutral Rating	02-06	MT
UBS Adjusts Price Target on Regeneron Pharmaceuticals to $1,090 from $1,112, Maintains Buy Rating	02-06	MT
Deutsche Bank Adjusts Price Target on Regeneron Pharmaceuticals to $880 From $870, Maintains Hold Rating	02-06	MT
Truist Adjusts Price Target on Regeneron Pharmaceuticals to $1,135 From $1,045, Maintains Buy Rating	02-05	MT
RBC Lifts Price Target on Regeneron Pharmaceuticals to $1,110 From $1,076 Amid 'Underappreciated' Growth Prospects for Dupixent; Outperform Kept	02-05	MT
Barclays Adjusts Regeneron Pharmaceuticals' Price Target to $1,050 From $1,020, Keeps Overweight Rating	02-05	MT
Piper Sandler Adjusts Regeneron Pharmaceuticals' Price Target to $1,016 From $956, Keeps Overweight Rating	02-05	MT
Wells Fargo Adjusts Regeneron Pharmaceuticals' Price Target to $1,050 From $980, Keeps Overweight Rating	02-05	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Analyst Reco.

Filters